Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours
(2019)
Journal Article
Ordonez, L. D., Hay, T., McEwen, R., Polanska, U. M., Hughes, A., Delpuech, O., …Smalley, M. J. (2019). Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours. Oncotarget, 10(27), 2586-2606. https://doi.org/10.18632/oncotarget.26830
Tumours defective in the DNA homologous recombination repair pathway can be effectively treated with poly (ADP-ribose) polymerase (PARP) inhibitors; these have proven effective in clinical trials in patients with BRCA gene function-defective cancers.... Read More about Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.